How should we proceed with disease-modifying treatments for multiple sclerosis?

Andersson, P B

How should we proceed with disease-modifying treatments for multiple sclerosis? [electronic resource] - Lancet (London, England) Mar 1997 - 586-7 p. digital

Publication Type: Comment; Journal Article

0140-6736

10.1016/S0140-6736(05)61562-0 doi


Clinical Trials as Topic
Disease Progression
Glatiramer Acetate
Humans
Immunoglobulins, Intravenous--therapeutic use
Immunosuppressive Agents--therapeutic use
Interferon beta-1a
Interferon beta-1b
Interferon-beta--therapeutic use
Multiple Sclerosis--immunology
Peptides--therapeutic use